Loading company
Nektar Therapeutics
NKTR · Nasdaq · ·
Next earnings: November 5, 2026
$59.31-1.8%Sep 29 close
- 1M
- -17.3%
- 6M
- -21.7%
- 1Y
- +0.8%
- 5Y
- -79.0%
NKTR · Nasdaq · ·
Next earnings: November 5, 2026
$59.31-1.8%Sep 29 close
Nektar Therapeutics is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $10.1M | $11.2M | -9.34% |
| Profit | -$40.6M | -$41.6M | +2.33% |
| Profit per share | -$1.23 | -$2.95 | +58.31% |
| Free Cash Flow | -$75.9M | -$45.8M | -65.73% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nektar Therapeutics’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Nektar Therapeutics has no earnings call transcript available.